Primary hyperparathyroidism and vitamin D deficiency

Cover Page

Cite item

Full Text

Abstract

Primary hyperparathyroidism (PHPT) is the third most common endocrine disease after diabetes mellitus and thyroid pathology. Recent epidemiological and experimental data have shown that long-term maintenance of low vitamin D levels in the blood can lead to the development of hyperplastic processes in the cells of the parathyroid glands, followed by autonomous production of parathyroid hormone. In PHPT vitamin D insufficiency or deficiency according to various sources occurs with a frequency of 53–77% of cases. The literature review indicates more severe disease in patients with concomitant vitamin D deficiency. The expediency of preoperative assessment of vitamin D levels in all patients with PHPT in order to minimize the risk of hypocalcemia after parathyroidectomy is discussed. This article presents the relationship between vitamin D deficiency and PHPT, as well as possible methods for correcting vitamin D deficiency in PHPT. Molecular and cellular mechanisms of the occurrence of pathological processes in the parathyroid glands under conditions of low vitamin D levels are presented.

About the authors

Gyuzel E. Runova

Sechenov First Moscow State Medical University (Sechenov University)

Email: olga.golounina@mail.ru
ORCID iD: 0000-0003-2144-8595

канд. мед. наук, ассистент каф. эндокринологии №1.

Russian Federation, Moscow

Olga O. Golounina

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: olga.golounina@mail.ru
ORCID iD: 0000-0003-2320-1051

студентка 4-го курса ЦИОП «Международная школа “Медицина будущего”»

Russian Federation, Moscow

Irina V. Glinkina

Sechenov First Moscow State Medical University (Sechenov University)

Email: olga.golounina@mail.ru
ORCID iD: 0000-0001-8505-5526

канд. мед. наук, доц. каф. эндокринологии №1

Russian Federation, Moscow

Valentin V. Fadeev

Sechenov First Moscow State Medical University (Sechenov University)

Email: olga.golounina@mail.ru
ORCID iD: 0000-0002-3026-6315

чл.-кор. РАН, д-р мед. наук, проф., дир. Клиники эндокринологии, зав. каф. эндокринологии №1.

Russian Federation, Moscow

References

  1. Дедов И.И., Мельниченко Г.А., Мокрышева Н.Г., и др. Первичный гиперпаратиреоз: клиника, диагностика, дифференциальная диагностика, методы лечения. Проблемы эндокринологии. 2016;62(6):40-77 [Dedov II, Melnichenko GA, Mokrysheva NG, et al. Primary hyperparathyroidism: the clinical picture, diagnostics, differential diagnostics, and methods of treatment. Problems of Endocrinology. 2016;62(6):40-77 (in Russian)]. doi: 10.14341/probl201662640-77
  2. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press, 2011.
  3. Плещева А.В., Пигарова Е.А., Дзеранова Л.К. Витамин D и метаболизм: факты, мифы и предупреждения. Ожирение и метаболизм. 2012;9(2):33-42 [Plescheva AV, Pigarova EA, Dzeranova LK. Vitamin D and metabolism: facts, myths and misconceptions. Obesity and Metabolism. 2012;9(2):33-42 (in Russian)]. doi: 10.14341/omet2012233-42
  4. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии. 2016;62(4):60-84 [Pigarova EA, Rozhinskaya LYa, Belaya JE, et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84 (in Russian)]. doi: 10.14341/probl201662460-84
  5. Walker MD, Cong E, Lee JA, et al. Low vitamin D levels have become less common in primary hyperparathyroidism. Osteoporos Int. 2015;26(12):2837-43. doi: 10.1007/s00198-015-3199-6
  6. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3580-94. doi: 10.1210/jc.2014-1415
  7. Bilezikian JP, Meng X, Shi Y, Silverberg SJ. Primary hyperparathyroidism in women: A tale of two cities – New York and Beijing. Int J Fertil Womens Med. 2000;45(2):158-65.
  8. Rao DS, Agarwal G, Talpos GB, et al. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: A global perspective. J Bone Miner Res. 2002;17(2):75-80.
  9. Jha S, Jayaraman M, Jha A, et al. Primary hyperparathyroidism: A changing scenario in India. Indian J of Endocrinol Metab. 2016;20(1):80-3. doi: 10.4103/2230-8210.172237
  10. Norman J. Increased calcium intake may reduce risk of primary hyperparathyroidism. BMJ. 2012;345:e6646. doi: 10.1136/bmj.e6646
  11. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med. 1999;107(6):561-7. doi: 10.1016/s0002-9343(99)00294-6
  12. Walker MD, Cong E, Lee JA, et al. Vitamin D in primary hyperparathyroidism: Effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab. 2015;100(9):3443-51. doi: 10.1210/jc.2015-2022
  13. Özbey N, Erbil Y, Ademoğlu E, et al. Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg. 2006;30(3):321-6. doi: 10.1007/s00268-005-0239-y
  14. Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res. 2007;22(2):100-4. doi: 10.1359/jbmr.07s202
  15. Пампутис С.Н., Александров Ю.К., Лопатникова Е.Н. Значение витамина D в диагностике и лечении гиперпаратиреоза. Альманах клинической медицины. 2014.;32:56-60 [Pamputis SN, Alexandrov YuK, Lopatnikova EN. Vitamin D value in diagnosis and treatment of hyperparathyroidism. Almanac of Clinical Medicine. 2014;32:56-60 (in Russian)]. doi: 10.18786/2072-0505-2014-32-56-60
  16. Kontogeorgos G, Trimpou P, Laine CM, et al. Normocalcaemic, vitamin D-sufficient hyperparathyroidism – high prevalence and low morbidity in the general population: A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden. Clin Endocrinol (Oxf). 2015;83(2):277-84. doi: 10.1111/cen.12819
  17. Salcuni AS, Battista C, Pugliese F, et al. Normocalcemic primary hyperparathyroidism: an update. Minerva Endocrinol. 2020;26. doi: 10.23736/S0391-1977.20.03215-0
  18. Schini M, Jacques RM, Oakes E, et al. Normocalcemic hyperparathyroidism: Study of its prevalence and natural history. J Clin Endocrinol Metab. 2020;105(4):1171-86. doi: 10.1210/clinem/dgaa084
  19. Zavatta G, Clarke BL. Normocalcemic hyperparathyroidism: A heterogeneous disorder often misdiagnosed? JBMR Plus. 2020;4(8):e10391. doi: 10.1002/jbm4.10391
  20. Babwah F, Buch HN. Normocalcaemic primary hyperparathyroidism: A pragmatic approach. J Clin Pathol. 2018;71(4):291-7. doi: 10.1136/jclinpath-2017-204455
  21. Pawlowska M, Cusano NE. An overview of normocalcemic primary hyperparathyroidism. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):413-21. doi: 10.1097/MED.0000000000000198
  22. Cusano NE, Cipriani C, Bilezikian JP. Management of normocalcemic primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(6):837-45. doi: 10.1016/j.beem.2018.09.009
  23. Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine. 2017;55(1):3-5. doi: 10.1007/s12020-016-1169-1
  24. Jenkinson C. The vitamin D metabolome: An update on analysis and function. Cell Biochem Funct. 2019;37(6):408-23. doi: 10.1002/cbf.3421
  25. Henry HL. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab. 2011;25(4):531-41. doi: 10.1016/j.beem.2011.05.003
  26. Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D and FGF23. Annu Rev Med. 2010;61(1):91-104. doi: 10.1146/annurev.med.051308.111339
  27. Khundmiri SJ, Murray RD, Lederer E. PTH and vitamin D. Compr Physiol. 2016;6(2):561-601. doi: 10.1002/cphy.c140071
  28. Samuel S, Sitrin MD. Vitamin D’s role in cell proliferation and differentiation. Nutr Rev. 2008;66(10 Suppl. 2):116-24. doi: 10.1111/j.1753-4887.2008.00094.x
  29. Pendás-Franco N, García JM, Peña C, et al. DICKKOPF-4 is induced by TCF/β-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1α,25-dihydroxyvitamin D3. Oncogene. 2008;27(32):4467-77. doi: 10.1038/onc.2008.88
  30. Groschel C, Aggarwal A, Tennakoon S, et al. Effect of 1,25-dihydroxyvitamin D3 on the Wnt pathway in non-malignant colonic cells. J Steroid Biochem Mol Biol. 2016;155:224-30. doi: 10.1016/j.jsbmb.2015.02.011
  31. An BS, Tavera-Mendoza LE, Dimitrov V, et al. Stimulation of Sirt1-regulated FoxO protein function by the ligand-bound vitamin D receptor. Mol Cell Biol. 2010;30(20):4890-900. doi: 10.1128/MCB.00180-10
  32. Chen A, Davis BH, Sitrin MD, et al. Transforming growth factor-β1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)2D3. Am J Physiol Gastrointest Liver Physiol. 2002;283(4):864-74. doi: 10.1152/ajpgi.00524.2001
  33. Bhoora S, Pather Y, Marais S, Punchoo R. Cholecalciferol inhibits cell growth and induces apoptosis in the CaSki cell line. Med Sci (Basel). 2020;8(1):12. doi: 10.3390/medsci8010012
  34. Bhoora S, Punchoo R. Policing cancer: Vitamin D arrests the cell cycle. Int J Mol Sci. 2020;21(23):9296. doi: 10.3390/ijms21239296
  35. Sergeev IN. Vitamin D and cellular Ca2+ signaling in breast cancer. Anticancer Res. 2012;32(1):299-302.
  36. Canaff L, Hendy GN. Human calcium-sensing receptor gene: Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem. 2002;277(33):30337-50. doi: 10.1074/jbc.M201804200
  37. Moosgaard B, Vestergaard P, Heickendorff L, et al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005;63(5):506-13. doi: 10.1111/j.1365-2265.2005.02371.x
  38. Battista C, Guarnieri V, Carnevale V, et al. Vitamin D status in primary hyperparathyroidism: effect of genetic background. Endocrine. 2017;55(1):266-72. doi: 10.1007/s12020-016-0974-x
  39. Demiralay E. Comparison of proliferative activity in parathyroid glands in primary and secondary hyperparahyroidism. Acta Endocrinol (Buchar). 2011;7(4):513-22. doi: 10.4183/aeb.2011.513
  40. Yamashita H, Noguchi S, Uchino S, et al. Vitamin D status in Japanese patients with hyperparathyroidism: Seasonal changes and effect on clinical presentation. World J Surg. 2002;26(8):937-41. doi: 10.1007/s00268-002-6622-z
  41. Tassone F, Castellano E, Gianotti L, et al. Vitamin D deficiency does not affect the likelihood presurgical localization in asymptomatic primary hyperparathyroidism. Endocr Pract. 2016;22(2):205-9. doi: 10.4158/EP15977.OR
  42. Viccica G, Cetani F, Vignali E, et al. Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. Endocrine. 2017;55(1):256-65. doi: 10.1007/s12020-016-0931-8
  43. Moosgaard B, Christensen SE, Vestergaard P, et al. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2008;68(5):707-15. doi: 10.1111/j.1365-2265.2007.03109.x
  44. Walker MD, Nishiyama KK, Zhou B, et al. Effect of low vitamin D on volumetric bone mineral density, bone microarchitecture and stiffness in primary hyperparathyroidism. J Clin Endocrinol Metab. 2016;101(3):905-13. doi: 10.1210/jc.2015-4218
  45. Walker MD, Saeed I, Lee JA, et al. Effect of concomitant vitamin D deficiency or insufficiency on lumbar spine volumetric bone mineral density and trabecular bone score in primary hyperparathyroidism. Osteoporos Int. 2016;27(10):3063-71. doi: 10.1007/s00198-016-3637-0
  46. Aktas YB, Akyel A, Kan E, et al. Cardiac structure and functions in patients with asymptomatic primary hyperparathyroidism. J Endocrinol Invest. 2013;36(10):848-52. doi: 10.3275/8961
  47. Walker MD, Cong E, Kepley A, et al. Association between serum 25-hydroxyvitamin D level and subclinical cardiovascular disease in primary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99(2):671-80. doi: 10.1210/jc.2013-3523
  48. Stamatelopoulos K, Athanasouli F, Pappa T, et al. Hemodynamic markers and subclinical atherosclerosis in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99(8):2704-11. doi: 10.1210/jc.2013-4273
  49. Ring M, Farahnak P, Gustavsson, et al. Arterial structure and function in mild primary hyperparathyroidism is not directly related to parathyroid hormone, calcium or vitamin D. PLoS One. 2012;7(7):e39519. doi: 10.1371/journal.pone.0039519
  50. Norenstedt S, Pernow Y, Brismar K, et al. Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur J Endocrinol. 2013;169(6):795-804. doi: 10.1530/EJE-13-0547
  51. Åberg V, Norenstedt S, Zedenius J, et al. Health-related quality of life after successful surgery for primary hyperparathyroidism: no additive effect from vitamin D supplementation: results of a double-blind randomized study. Eur J Endocrinol. 2015;172(2):181-7. doi: 10.1530/EJE-14-0757
  52. Rolighed L, Rejnmark L, Sikjaer T, et al. No beneficial effects of vitamin D supplementation on muscle function or quality of life in primary hyperparathyroidism: results from a randomized controlled trial. Eur J Endocrinol. 2015;172(5):609-17. doi: 10.1530/EJE-14-0940
  53. Kandil E, Tufaro AP, Carson KA, et al. Correlation of plasma 25-hydroxyvitamin D levels with severity of primary hyperparathyroidism and likelihood of parathyroid adenoma localization on sestamibi scan. Arch Otolaryngol Head Neck Surg. 2008;134(10):1071-5. doi: 10.1001/archotol.134.10.1071
  54. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561-9. doi: 10.1210/jc.2014-1413
  55. Shah VN, Shah CS, Bhadada SK, Rao DS. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf). 2014;80(6):797-803. doi: 10.1111/cen.12398
  56. Rolighed L, Rejnmark L, Sikjaer T, et al. Vitamin D treatment in primary hyperparathyroidism: A randomized placebo controlled trial. J Clin Endocrinol Metab. 2014;99(3):1072-80. doi: 10.1210/jc.2013-3978

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Regulation of vitamin D synthesis and metabolism and its active forms.

Download (283KB)
Indexing metadata
3. Fig. 2. 1,25 (OH)2D3-induced signaling pathways involved in the regulation of cell proliferation and apoptosis.

Download (382KB)
Indexing metadata

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies